Biotech Holdings Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (158)	4/27/1999 3:37:00 PM
From: Mike Heimbuch	Read Replies (1) of 224

Hello tommysdad Knowing that you have taken a cautious approach to this company - I commend you for it. Contrary to what you might read on this board - it is unlikely that any data related to the Diab clinical testing -supposedly to be finished in May - will be made public in the near future. The company has certainly not led anyone to believe that this is the case. Details of the trial and the extent of supplemental information needed for registration in Brazil have not been revealed. I will say that according to Biobras - who has signed up for Brazilian distribution - the Brazilian government arm responsible for registration approval seems to be in a state of disarray - and I was given no indication that they expected approvals in a forseeable time frame. Incidentally, the same situation exists in China from what we have been told - ie - the government arm responsible for deciding which drugs will qualify for gov. reimbursement is undergoing some sort of upheaval with no resolution time being sure. The idea that some major pharma is going to snatch an opportunity for N. American - European distribution of Diab in the near future is fairly unlikely considering that Bob Rieveley already has a tremendously full plate just paying attention to the tasks and timelines in S.America and China. He is in no hurry to give away this company nor take undue risk. What may well happen in the interim is that the Ira Miller group who is promoting Biotech may be able to attract some serious $$ into the arena and stock prices may benefit. At the same time - someone (who may well have bought in at .10 a share) is finding it expedient to sell at the lowest prices we have seen in a few years. It would appear that Biotech is doing everything it possibly can to upgrade the revenue stream from the packaging division to support their independant pursuit of bringing Diab II to the world. Confidence in this stock - if based on confidence of the revealed material on DIAB II - is quite a stretch. On the other hand - the company has persevered and advanced. Whether or not this drug will find the acceptance and route leading to gigantic sales is yet undetermined. Mike H

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next